Canaccord analyst William Plovanic lowered the firm’s price target on Edwards Lifesciences (EW) to $85 from $87 and keeps a Hold rating on the shares. The firm noted management raised its overall revenue, total TAVR, and adjusted EPS guidance ranges slightly ahead of estimates. Overall revenue growth guidance was raised from 9% year-over-year at the midpoint to 10%, which now implies $6.7B and is slightly ahead of estimates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $87 from $85 at Baird
- Edwards Lifesciences price target lowered to $100 from $103 at BofA
- Closing Bell Movers: Intel jumps 19% on blowout earnings
- Edwards Lifesciences sees Q2 EPS 70c-76c, consensus 75c
- Edwards Lifesciences reports Q1 EPS 78c, consensus 73c